$60 million to be spent on DTC ads for Sepracor sleep drug

Share this article:
Sepracor will spend an estimated $60 million to advertise its new insomnia drug Lunesta directly to consumers, according to a Wall Street Journal report. The drug was approved by the FDA Wednesday.
Handling the DTC account for Lunesta is McCann-Erickson, with professional work done by Torre Lazur McCann Healthcare.
Lunesta was formerly known as Estorra. Its name was changed to avoid confusion with another drug on the market, a company official said. 
Lunesta will enter the $2 billion market for sleep aids, which is led by Sanofi-Aventis' Ambien. Ambien spent $65 million on U.S. media in 2002, according to Nielsen-Monitor Plus.
Analysts estimate Lunesta could start out with annual sales of $400 million, rising to $750 million or more.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.